56
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Plasma fibronectin deficiency impedes atherosclerosis progression and fibrous cap formation

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Atherosclerotic lesions are asymmetric focal thickenings of the intima of arteries that consist of lipids, various cell types and extracellular matrix (ECM). These lesions lead to vascular occlusion representing the most common cause of death in the Western world. The main cause of vascular occlusion is rupture of atheromatous lesions followed by thrombus formation. Fibronectin (FN) is one of the earliest ECM proteins deposited at atherosclerosis-prone sites and was suggested to promote atherosclerotic lesion formation. Here, we report that atherosclerosis-prone apolipoprotein E-null mice lacking hepatocyte-derived plasma FN (pFN) fed with a pro-atherogenic diet display dramatically reduced FN depositions at atherosclerosis-prone areas, which results in significantly smaller and fewer atherosclerotic plaques. However, the atherosclerotic lesions from pFN-deficient mice lacked vascular smooth muscle cells and failed to develop a fibrous cap. Thus, our results demonstrate that while FN worsens the course of atherosclerosis by increasing the atherogenic plaque area, it promotes the formation of the protective fibrous cap, which in humans prevents plaques rupture and vascular occlusion.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: not found
          • Article: not found

          Atherosclerosis. the road ahead.

            • Record: found
            • Abstract: found
            • Article: not found

            Inducible gene targeting in mice.

            A method of gene targeting that allows the inducible inactivation of a target gene in mice is presented. The method uses an interferon-responsive promoter to control the expression of Cre recombinase. Here, Cre was used to delete a segment of the DNA polymerase beta gene flanked by IoxP recombinase recognition sites. Deletion was complete in liver and nearly complete in lymphocytes within a few days, whereas partial deletion was obtained in other tissues. This method can be used for the inducible inactivation of any other gene in vivo.
              • Record: found
              • Abstract: found
              • Article: not found

              Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin.

              To examine the role of fibronectin in vivo, we have generated mice in which the fibronectin gene is inactivated. Heterozygotes have one half normal levels of plasma fibronectin, yet appear normal. When homozygous, the mutant allele causes early embryonic lethality, proving that fibronectin is required for embryogenesis. However, homozygous mutant embryos implant and initiate gastrulation normally including extensive mesodermal movement. Neural folds also form but the mutant embryos subsequently display shortened anterior-posterior axes, deformed neural tubes and severe defects in mesodermally derived tissues. Notochord and somites are absent; the heart and embryonic vessels are variable and deformed, and the yolk sac, extraembryonic vasculature and amnion are also defective. These abnormalities can be interpreted as arising from fundamental deficits in mesodermal migration, adhesion, proliferation or differentiation as a result of the absence of fibronectin. The nature of these embryonic defects leads to reevaluation of suggested roles for fibronectin during early development based on results obtained in vitro and in embryos of other species.

                Author and article information

                Journal
                EMBO Mol Med
                EMBO Mol Med
                emmm
                EMBO Molecular Medicine
                WILEY-VCH Verlag (Weinheim )
                1757-4676
                1757-4684
                July 2012
                19 April 2012
                : 4
                : 7
                : 564-576
                Affiliations
                [1 ]simpleDepartment for Molecular Medicine, Max Planck Institute of Biochemistry Martinsried, Germany
                [2 ]simpleWalter-Brendel-Centre of Experimental Medicine, Ludwig-Maximilians University Munich Munich, Germany
                [3 ]simpleDepartment of Clinical Sciences Malmö, Skåne University Hospital, Lund University Malmö, Sweden
                [4 ]simpleInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University Munich Munich, Germany
                Author notes
                * Corresponding author: Tel: +49 89 85782424; Fax: +49 89 85782422; E-mail: Faessler@ 123456biochem.mpg.de
                [†]

                These authors contributed equally to this work.

                [‡]

                Present address: U3 Pharma GmbH, Martinsried, Germany

                Article
                10.1002/emmm.201200237
                3407945
                22514136
                885293d9-712c-495e-9788-19a954057b60
                Copyright © 2012 EMBO Molecular Medicine
                History
                : 23 September 2011
                : 29 February 2012
                : 01 March 2012
                Categories
                Research Articles

                Molecular medicine
                inflammation,fibronectin,fibrous cap,atherosclerosis,migration
                Molecular medicine
                inflammation, fibronectin, fibrous cap, atherosclerosis, migration

                Comments

                Comment on this article

                Related Documents Log